Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04335292
Title Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mark Vincent
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Osimertinib

Age Groups: senior | adult
Covered Countries CAN

Facility Status City State Zip Country Details
BC Cancer Agency Recruiting Vancouver British Columbia V5Z 4E6 Canada Details
Lions Gate Hospital Recruiting Vancouver British Columbia V7L 2L7 Canada Details
William Osler Health System Recruiting Brampton Ontario L6R 3J7 Canada Details
Hamilton Health Sciences Centre, Juravinski Cancer Centre Not yet recruiting Hamilton Ontario L8V 5C2 Canada Details
Grand River Regional Cancer Centre Recruiting Kitchener Ontario N2G 1G3 Canada Details
London Regional Cancer Program of the Lawson Health Research Institute Recruiting London Ontario N6A 5W9 Canada Details
Durham Regional Cancer Centre, Lakeridge Health Recruiting Oshawa Ontario L1G 2B9 Canada Details
The Ottawa Hospital Recruiting Ottawa Ontario K1H 8L6 Canada Details
Sunnybrook Research Institute Recruiting Toronto Ontario M4N 3M5 Canada Details
Princess Margaret Hospital Recruiting Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field